tldrdailynews.com logo

Pancreatic cancer drug shows early promise against lung cancer in NEJM trial

1 min read
Source: NBC News
Pancreatic cancer drug shows early promise against lung cancer in NEJM trial
Photo: NBC News
TL;DR Summary

An early NEJM-published trial found that a drug approved for pancreatic cancer shrank tumors in about one-third of patients with advanced non-small-cell lung cancer who had already undergone standard treatments; larger trials are underway to confirm its safety and effectiveness.

Topics:business#clinical-trial#health#lung-cancer#nejm#non-small-cell-lung-cancer#pancreatic-cancer
Share this article
  1. Newly approved pancreatic cancer drug shows promise in lung cancer  NBC News
  2. Daraxonrasib Demonstrates Initial Antitumor Activity in RAS-Mutant Lung Cancer | Newswise  Newswise
  3. We’re reading about drug pricing deals, a new cancer therapy approval, and more  STAT
  4. New pancreatic cancer drug carries a $39,800 monthly list price: What to know  finance.yahoo.com
  5. Pashtoon Kasi: Daraxonrasib Offers a New Option for Pancreatic Cancer Patients  Oncodaily

Reading Insights

Total Reads

1

Unique Readers

4

Time Saved

385 min

vs 386 min read

Condensed

100%

77,111 → 40 words

Want the full story? Read the original article

Read on NBC News